The European Commission has granted approval for Amgen’s BLINCYTO® (blinatumomab) for the treatment of pediatric patients with certain forms of B cell acute lymphoblastic leukaemia (ALL).
So far, children with relapsed or refractory ALL had limited treatment options beyond chemotherapy. The approval provides them with a new immunotherapy option that helps activate their body’s immune system against cancer. The market authorization is based on a Phase I/II Study evaluating the safety and efficacy of BLINCYTO in nearly 100 pediatric patients.
Further information:
See Amgen's press release